摘要
目的：研究18F-FDG PET/CT显像在卵巢癌术后随访中的价值及与血清CA125检测的关系。方法：对45例卵巢癌术后患者行18F-FDG PET/CT显像及血清CA125检测，与手术病理或临床随访结果比较判断其诊断复发、转移灶的准确性并比较二者之间的关系。结果：18F-FDG PET/CT显像诊断卵巢癌复发、转移的敏感性、特异性、准确性、阳性预测值、阴性预测值分别为90.3%（28/31）、92.8%（13/14）、91.1%（41/45）、96.5%（28/29）和81.5%（13/16）。血清CA125诊断卵巢癌复发、转移的敏感性、特异性、准确性、阳性预测值和阴性预测值分别为74.2%（23/31）、78.5%（11/14）、75.5%（34/45）、88.4%（23/26）和57.9%（11/19）。18F-FDG PET/CT显像与血清CA125检测结果有一定相关性，26例血清CA125升高者中23例PET/CT检查显示数目不等的复发；19例CA125正常患者，8例PET/CT检查显示复发，二者有显著性差异（χ2=11.007，P=0.001）。10例血清CA125≤100 U/mL的复发患者病灶数均较少，90%（9/10）为1～3个；21例CA125>100 U/mL复发患者病灶数80.9%（17/21)为3个以上，二者有显著性差异（χ2=14.006，P=0）。结论：18F-FDG PET/CT显像在卵巢癌术后随访中具有重要临床价值，与血清CA125检测有一定的相关性和互补性。
Abstract
Objective: To evaluate the value of 18F-FDG PET/CT imaging in the follow-up of ovarian cancer after surgery and the relationship between PET/CT imaging and serum CA125 assay. Methods: 18F-FDG PET/CT and serum CA125 assay were performed in 45 postoperative patients with ovarian cancer. The diagnostic value was determined according to the results of surgical pathology or clinical follow-up. Results: The sensitivity, specificity, accuracy, positive predictive value, negative predictive value of 18F-FDG PET/CT imaging for detecting ovarian cancer recurrence or metastasis were 90.3%(28/31), 92.8%(13/14), 91.1%(41/45), 96.5%(28/29) and 81.5%(13/16), respectively. And the sensitivity, specificity, accuracy, positive predictive value, negative predictive value of serum CA125 assay for detecting ovarian cancer recurrence or metastasis were 74.2%(23/31), 78.5%(11/14), 75.5%(34/45), 88.4%(23/26) and 57.9%(11/19), respectively. There was a correlation between 18F-FDG PET/CT imaging and serum CA125 assay. Among 26 patients with increased serum CA125, recurrent lesions were detected by 18F-FDG PET/CT in 23 patients. However, among 19 patients with normal CA125, only 8 patients were detected to have recurrent lesions by 18F-FDG PET/CT. The recurrence detected by 18F-FDG PET/CT was statistically different between increased serum CA125 group and normal CA125 group(χ2=11.007，P=0.001). Fewer recurrent lesions were found in 10 patients with serum CA125≤100 U/mL. In our study, 90%(9/10) of patients with serum CA125≤100 U/mL had 1~3 recurrent lesions. More than 3 recurrent lesions were found in 21 patients with serum CA125＞100 U/mL. The number of recurrent lesions was statistically different between the group with serum CA125≤100 U/mL and that with serum CA125＞100 U/mL(χ2=14.006, P=0). Conclusion: 18F-FDG PET/CT possesses an important clinical priority for following-up patients with ovarian cancer after surgery. There was a correlation between 18F-FDG PET/CT imaging and serum CA125 assay. 18F-FDG PET/CT and serum CA125 assay can complement each other.
关键词
卵巢肿瘤 /
抗原 /
肿瘤相关 /
碳水化合物 /
正电子发射断层显像术 /
体层摄影术 /
X线计算机
Key words
Ovarian neoplasms /
Antigens /
tumor-associated /
carbohydrate /
Positron-emission tomography /
Tomography /
X-ray computed
邓智勇;周友俊;孙 华;汪 春;谢 燃;赵 升;李 潇.
18F-FDG PET/CT显像在卵巢癌术后随访中的价值及与血清CA125检测的关系[J]. 中国临床医学影像杂志. 2012, 23(1): 17-20
DENG Zhi-yong;ZHOU You-jun;SUN Hua;WANG Chun;XIE Ran;ZHAO Shen;LI Xiao.
The value of 18F-FDG PET/CT imaging in the follow-up of ovarian cancer aftersurgery and the relationship between PET/CT imaging and serum CA125 assay[J]. Journal of China Clinic Medical Imaging. 2012, 23(1): 17-20
中图分类号：
Ｒ737.31
R817.4
Ｒ814.42
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
